Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
The purpose of this study is to find the highest dose of the investigational immunotherapy drug REGN7075 that can be given alone and in combination with cemiplimab in people with inoperable or metastatic solid tumors. Patients will either receive REGN7075 alone followed by REGN7075 plus cemiplimab, or only combination treatment with REGN7075 plus cemiplimab. Both drugs are given intravenously (by vein).
The purpose of this study is to find the highest dose of the investigational drug LOXO-435 that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment and contain a change in the FGFR3 gene. LOXO-435 targets cells with this abnormality and blocks the activity of FGFR3, a protein that plays a role in cancer growth. Inhibiting this protein could slow or stop the growth of cancer. LOXO-435 is taken orally (by mouth).
Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.
Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.
Researchers want to find the best dose of HC-7366 to use alone and with belzutifan in people with kidney cancer. The people in this study have advanced renal cell carcinoma (kidney cancer) that keeps growing after prior treatments. The cancer either cannot be removed (is inoperable) or has metastasized (spread).
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
This clinical trial explores a novel approach to treating mantle cell lymphoma (MCL). Researchers are integrating targeted agents into standard induction and maintenance chemoimmunotherapy. The people in this study have MCL that has not yet been treated.
